GRI Bio (GRI)
Nasdaq Market Open
GRI Bio, Inc. is a clinical-stage biotechnology company developing therapies for serious diseases in which the immune system is abnormally activated. The company focuses on inflammatory, fibrotic, and autoimmune conditions, where dysregulated immune responses can drive tissue damage and long-term disease progression. Its strategy centres on modulating Natural Killer T, or NKT, cells, a class of immune cells that can influence both inflammatory signalling and immune balance.
GRI Bio’s lead programme is GRI-0621, an oral small-molecule candidate designed as a dual agonist of retinoic acid receptor beta and gamma. The company is evaluating the compound for its ability to inhibit human type 1 NKT cell activity and help restore immune homeostasis. The active approach is related to tazarotene, a synthetic retinoid best known for dermatology uses such as psoriasis and acne, but GRI Bio is pursuing systemic applications in diseases where immune-driven inflammation and fibrosis are central features.
The company is also advancing GRI-0803, an oral candidate intended to activate type 2 NKT cells. This programme is aimed at autoimmune disorders and reflects GRI Bio’s broader interest in selectively adjusting immune pathways rather than broadly suppressing immunity. As a development-stage biotech, GRI Bio’s value is closely tied to preclinical and clinical progress, regulatory milestones, safety data, and its ability to secure capital or partnerships. Investors typically view the stock as a high-risk life sciences exposure, with potential upside linked to successful validation of its NKT cell-focused platform.
Last updated
- Market Cap
- 3.56M
- P/E
- —
- P/FCF
- —
- P/S
- —
- Enterprise Value
- -7.49M
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Address
- 2223 AVENIDA DE LA PLAYA, LA JOLLA, CA, 92037
GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment
Windtree Announces the Addition of Leanne Kelly to Its Board of Directors
GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds
GRI Bio Announces Exercise of Warrants
GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series - GlobeNewswire
GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment - GlobeNewswire
GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine
GRI Bio to Present at the 8th Annual IPF Summit
GRI Bio Announces Closing of $4.0 Million Public Offering
GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell Modulators
GRI Bio Announces Reverse Stock Split
GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs
GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)
GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)
GRI Bio to Present at Alliance Global Partner’s 2024 Healthcare Company Showcase
GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity
GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent
GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 3.56M
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- -7.49M
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 0.34
- P/S
P/S ratio compares a company's share price to its revenue per share.
- —
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- 0.69
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- —
- EPS
- -6.16
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -12.14M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -103.44%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -96.2%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 14.21
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 14.21
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 13.91
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 37.47K
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 2.01
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -2M | -2.66M | -3.37M | -2.9M | -3.05M |
| EBITDA | -2M | -2.66M | -3.36M | -2.9M | -3.05M |
| Net income | -2M | -2.66M | -3.36M | -2.89M | -3.05M |
| Basic EPS | -1.61 | -116.61 | -1.28 | -1.31 | -162.3 |
| Diluted EPS | -1.61 | -116.61 | -1.28 | -1.31 | -162.3 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 11.34M | 8.67M | 4.78M | 5.68M | 4.04M |
| Total liabilities | 794K | 2.66M | 2.79M | 2.35M | 2.84M |
| Total equity | 10.55M | 6.01M | 1.99M | 3.32M | 1.21M |
| Cash & equivalents | 11.05M | 8.23M | 4.06M | 5.12M | 3.28M |
| Current assets | 11.28M | 8.59M | 4.7M | 5.58M | 3.93M |
| Current liabilities | 794K | 2.64M | 2.76M | 2.31M | 2.78M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -3.69M | -2.97M | -2.31M | -3.17M | -1.74M |
| Investing cash flow | — | -3K | — | — | — |
| Financing cash flow | 6.5M | 7.15M | 1.25M | 5.01M | -11K |
| Change in cash | 2.82M | 4.17M | -1.07M | 1.84M | -1.75M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 8-K — GRI Bio, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G/A — GRI Bio, Inc. | View Filing | |
| edgar index | 10-Q — GRI Bio, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — GRI Bio, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — GRI Bio, Inc. | View Filing | |
| edgar index | 8-K — GRI Bio, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | UPLOAD — GRI Bio, Inc. | View Filing | |
| edgar index | S-8 — GRI Bio, Inc. | View Filing | |
| edgar index | S-3 — GRI Bio, Inc. | View Filing | |
| edgar index | 424B5 — GRI Bio, Inc. | View Filing | |
| edgar index | 8-K — GRI Bio, Inc. | View Filing | |
| edgar index | 10-K — GRI Bio, Inc. | View Filing | |
| edgar index | CORRESP — GRI Bio, Inc. | View Filing | |
| edgar index | EFFECT — GRI Bio, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | 8-K — GRI Bio, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — GRI Bio, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — GRI Bio, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — GRI Bio, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 424B5 — GRI Bio, Inc. | View Filing | |
| edgar index | 8-K — GRI Bio, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — GRI Bio, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G — GRI Bio, Inc. | View Filing | |
| edgar index | DEF 14A — GRI Bio, Inc. | View Filing | |
| edgar index | PRE 14A — GRI Bio, Inc. | View Filing | |
| edgar index | SCHEDULE 13G — GRI Bio, Inc. | View Filing | |
| edgar index | 8-K — GRI Bio, Inc. | View Filing | |
| edgar index | 424B4 — GRI Bio, Inc. | View Filing | |
| edgar index | 8-K — GRI Bio, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | EFFECT — GRI Bio, Inc. | View Filing | |
| edgar index | S-1/A — GRI Bio, Inc. | View Filing | |
| edgar index | 8-K — GRI Bio, Inc. | View Filing | |
| edgar index | CORRESP — GRI Bio, Inc. | View Filing | |
| edgar index | CORRESP — GRI Bio, Inc. | View Filing | |
| edgar index | S-1 — GRI Bio, Inc. | View Filing | |
| edgar index | 8-K — GRI Bio, Inc. | View Filing | |
| edgar index | 424B3 — GRI Bio, Inc. | View Filing | |
| edgar index | 8-K — GRI Bio, Inc. | View Filing | |
| edgar index | 10-Q — GRI Bio, Inc. | View Filing | |
| edgar index | 424B3 — GRI Bio, Inc. | View Filing | |
| edgar index | 4 — GRI Bio, Inc. | View Filing | |
| edgar index | 4 — GRI Bio, Inc. | View Filing | |
| edgar index | 4 — GRI Bio, Inc. | View Filing | |
| edgar index | 4 — GRI Bio, Inc. | View Filing | |
| edgar index | 4 — GRI Bio, Inc. | View Filing | |
| edgar index | 4 — GRI Bio, Inc. | View Filing | |
| edgar index | 4 — GRI Bio, Inc. | View Filing | |
| form 4 | Form 4 — Kelly Leanne | View Filing | |
| form 4 | Form 4 — Szekeres David Leslie | View Filing | |
| form 4 | Form 4 — Rongen Roelof | View Filing | |
| form 4 | Form 4 — SIMPSON CAMILLA V | View Filing | |
| form 4 | Form 4 — Baker David Charles | View Filing | |
| form 4 | Form 4 — Hertz Walter Marc | View Filing | |
| form 4 | Form 4 — Chaturvedi Vipin | View Filing | |
| edgar index | 4 — GRI Bio, Inc. | View Filing | |
| edgar index | 4 — GRI Bio, Inc. | View Filing | |
| edgar index | 4 — GRI Bio, Inc. | View Filing | |
| edgar index | 4 — GRI Bio, Inc. | View Filing | |
| edgar index | 4 — GRI Bio, Inc. | View Filing | |
| edgar index | 4 — GRI Bio, Inc. | View Filing | |
| edgar index | 4 — GRI Bio, Inc. | View Filing | |
| form 4 | Form 4 — Kelly Leanne | View Filing | |
| form 4 | Form 4 — SIMPSON CAMILLA V | View Filing | |
| form 4 | Form 4 — Chaturvedi Vipin | View Filing |